Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 5 months ago

Anticoagulation

Prevention & Chronic Conditions
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 1 week ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
David Wheeler
Research Area(s) / Expertise:

Chronic Kidney Disease

 Job title: Professor of Kidney Medicine
David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Prof Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated… View more
Job title: PhD, RD, FHFSA, FASPEN
Dr Salvatore Carbone, PhD, RDN, MS, FHFSA, FASPEN is an Associate Professor and Program Director of the Nutrition Program at the EVMS School of Health Professions, and an Associate Professor within the EVMS Division of Endocrine and Metabolic Disorders, Strelitz Diabetes Center, Department of Internal Medicine, at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University… View more
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 7 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 1 week ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview… View more

Heart Failure
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions